Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2025 vs. Q1 2025
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 395 | 2 | 4 | −389 |
| Shares | 103.1M | 416.6K | 52.8K | −102.6M (−99.9%) |
| Value | $13.6B | $55.0M | $4.15M | −$13.5B (−100.0%) |
2 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
None.
Sold out (389)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Showing the largest 100 of 389 by value.
Not filed for Q2 2025 yet (2)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| CIBRA Capital Ltd | 416,218 | $54.9M |
| Lindbrook Capital, LLC | 367 | $48.4K |